Edition:
United Kingdom

Moleculin Biotech Says Co Was Informed That Investigational NDA For Phase I Trial Of WP1066 Has Been Allowed By FDA


Monday, 4 Dec 2017 

Dec 4 (Reuters) - Moleculin Biotech Inc ::MOLECULIN BIOTECH SAYS ON NOV 29, CO WAS INFORMED THAT INVESTIGATIONAL NDA FOR PHASE I TRIAL OF WP1066 HAS BEEN ALLOWED BY FDA - SEC FILING.